Propolis is a bee product with a complex chemical composition that exhibits remarkable antifungal activity against C. albicans and can inhibit resistant biofilms thanks to its content of compounds such as flavonoids and phenolic acids. Its efficacy varies depending on its geographic origin: European propolis inhibits the initial formation of biofilms, while Brazilian propolis is superior at inhibiting mature biofilms. This product also possesses fungicidal and fungistatic properties comparable in efficacy to conventional drugs, such as nystatin, fluconazole, and chlorhexidine. The use of nanotechnology, such as nanoparticles or nanorods, has overcome the low solubility of propolis compounds, improving their bioavailability and reducing cell adhesion and hyphal formation. Moreover, the integration of propolis into dental materials demonstrate its versatility for preventing recurrent infections. The study of isolated compounds such as pinocembrin, galangin, and chrysin has facilitated the identification of specific mechanisms of action, and the application of molecules such as guttiferone E in photodynamic therapies and the discovery of quorum-sensing inhibitors, such as kaempferol, using in silico models have opened new avenues for blocking yeast communication and virulence. These findings position propolis as a multifaceted and promising therapeutic alternative, although there is a need to optimize formulations to ensure clinical safety and biocompatibility. In this review, we analyze research published around the world over the last 15 years on the effects of propolis against C. albicans biofilms.

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease with a rising global incidence and a considerable economic burden. Conventional treatments, such as steroidal anti-inflammatory drugs and immunosuppressants, are often associated with adverse effects and high costs. In this context, flavonoids—such as those identified in the chemical composition of propolis—are emerging as highly promising therapeutic alternatives. This review highlights how diverse classes of flavonoids, including flavones, flavonols, flavanones, isoflavones, and flavan-3-ols, mitigate colitis through multiple interconnected mechanisms. Their main actions include reducing inflammation by decreasing the levels of proinflammatory cytokines and modulating key signaling pathways; exerting potent antioxidant activity; and improving intestinal barrier integrity by increasing tight junction proteins and mucin production. Numerous studies reporting significant improvements in clinical parameters such as body weight, colon length, and the disease activity index are discussed. Innovation in formulations, for example, the use of nanoparticles, is crucial to improve the solubility, stability, and bioavailability of flavonoids, allowing for their targeted delivery to the inflamed colon. In summary, flavonoids are promising candidates for the development of complementary or alternative treatments for ulcerative colitis. Although further clinical evidence is needed to establish their safety and conditions for use in humans, the available preclinical results are promising.